December 10, 2024

In December 2024, Alverno Laboratories announced several important updates. They include the introduction of a new Quest Diagnostics urine drug monitoring test featuring additional novel psychoactive substances, the availability of a plastic collection bottle option for AFB cultures, and the launch of a new cystic fibrosis sputum culture. In addition, select Streptococcus pneumoniae antibody tests have been reactivated, a new assay formulation has remediated biotin interference in thyroglobulin testing, and 2025 CPT code changes will be implemented as of January 1, 2025. These developments may affect diagnostic workflows and ordering practices at healthcare facilities.